Comparative effectiveness of torsemide versus furosemide in heart failure patients: Insights from the PROTECT trial

Future Cardiology

Volumn 11, Issue 5, 2015, Pages 585-595

  Mentz, Robert J ^a,b   Velazquez, Eric J ^a,b   Metra, Marco ^c   McKendry, Colleen ^b   Chiswell, Karen ^b   Fiuzat, Mona ^a,b   Givertz, Michael M ^d   Voors, Adriaan A ^e   Teerlink, John R ^f   O'Connor, Christopher M ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

furosemide; heart failure; loop diuretics; outcomes; torsemide

Indexed keywords

FUROSEMIDE; TORASEMIDE; DIURETIC AGENT; SULFONAMIDE;

ABNORMAL BLOOD PRESSURE; AGED; ARTICLE; BREATHING DISORDER; CARDIOVASCULAR MORTALITY; CENTRAL VENOUS PRESSURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DYSPNEA; FEMALE; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; ORTHOPNEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; EPIDEMIOLOGY; EUROPE; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

AGED; DISEASE PROGRESSION; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; FOLLOW-UP STUDIES; FUROSEMIDE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SULFONAMIDES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84945568875     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.56     Document Type: Article

References (29)

1. Felker GM, Mentz RJ. Diuretics and ultrafltration in acute decompensated heart failure. J. Am. Coll. Cardiol. 59(24), 2145-2153 (2012).
2. Clasen W, Khartabil T, Imm S, Kindler J. Torasemide for diuretic treatment of advanced chronic renal failure. Arzneimittel-Forschung 38(1A), 209-211 (1988).
3. Uchida T, Yamanaga K, Nishikawa M, Ohtaki Y, Kido H, Watanabe M. Antialdosteronergic effect of torasemide. Eur. J. Pharmacol. 205(2), 145-150 (1991).
4. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 63(3), PL45-PL50 (1998).
5. Harada K, Izawa H, Nishizawa T et al. Benefcial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J. Cardiovasc. Pharmacol. 53(6), 468-473 (2009).
6. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fbrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol. 43(11), 2028-2035 (2004).
7. Kasama S, Toyama T, Hatori T et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 92(10), 1434-1440 (2006).
8. Murray MD, Deer MM, Ferguson JA et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am. J. Med. 111(7), 513-520 (2001).
9. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 4(4), 507-513 (2002).
10. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. Furosemide in primary care patients with chronic heart failure NYHA II to IV-effcacy and quality of life. Eur. J. Heart Fail. 5(6), 793-801 (2003).
11. Dinicolantonio J J. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol. 8(5), 707-728 (2012).
12. Bikdeli B, Strait KM, Dharmarajan K et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J. Am. Coll. Cardiol. 61(14), 1549-1550 (2013).
13. Weatherley BD, Cotter G, Dittrich HC et al. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective a1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J. Card. Fail. 16(1), 25-35 (2010).
14. Massie BM, O'Connor CM, Metra M et al. Rolofylline, an adenosine a1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363(15), 1419-1428 (2010).
15. ClinicalTrials Database: NCT00328692. https://clinicaltrials.gov/ct2/show/NCT00328692
16. ClinicalTrials Database: NCT00354458. https://clinicaltrials.gov/ct2/show/NCT00354458?term=NCT00354458 &rank=1
17. Cleland JG, Chiswell K, Teerlink JR et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the placebo-controlled randomized study of the selective a1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function (PROTECT) study. Circ. Heart Fail. 7(1), 76-87 (2014).
18. O'Connor CM, Mentz RJ, Cotter G et al. The PROTECT in-hospital risk model: 7 day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur. J. Heart Fail. 14(6), 605-612 (2012).
19. Lunceford JK, Davidian M. Stratifcation and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat. Med. 23(19), 2937-2960 (2004).
20. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative-effectiveness analyses with observational databases. Med. Care 45(10), S103-S107 (2007).
21. Buggey J, Mentz RJ, Pitt B et al. A reappraisal of loop diuretic choice in heart failure patients. Am. Heart J. 169(3), 323-333 (2015).
22. Solomon SD, Dobson J, Pocock S et al. Infuence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116(13), 1482-1487 (2007).
23. Devore AD, Hammill BG, Sharma PP et al. In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. J. Am. Heart Assoc. 3(4), (2014).
24. Stroupe KT Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmaco Economics 17(5), 429-440 (2000).
25. Lopez B, Querejeta R, Gonzalez A, Beaumont J, Larman M, Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 53(2), 236-242 (2009).
26. Lopez B, Gonzalez A, Beaumont J, Querejeta R, Larman M, Diez J. Identifcation of a potential cardiac antifbrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 50(9), 859-867 (2007).
27. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 62(16), e147-e239 (2013).
28. Mentz RJ, Cotter G, Cleland JG et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in eastern Europe and Russia in the PROTECT trial. Eur. J. Heart Fail. 16 (6), 614-624 (2014).
29. Pfeffer MA, Claggett B, Assmann SF et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1), 34-42 (2015).